Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease

Clinical Hemorheology and Microcirculation

Volumn 50, Issue 3, 2012, Pages 179-187

  Magyar, K ^a   Halmosi, R ^a   Palfi, A ^a   Feher, G ^a   Czopf, L ^a   Fulop, A ^a   Battyany, I ^a   Sumegi, B ^a   Toth, K ^a   Szabados, E ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

cardioprotection; endothelial dysfunction; left ventricular diastolic function; platelet aggregation; red blood cell deformability; Resveratrol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RESVERATROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BLOOD VISCOSITY; BRACHIAL ARTERY; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEMATOCRIT; HUMAN; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SHEAR STRESS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VASCULAR ENDOTHELIUM;

AGED; ANTIOXIDANTS; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ERYTHROCYTE DEFORMABILITY; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLACEBOS; PLATELET AGGREGATION; STILBENES; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 84860558348     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-2011-1424     Document Type: Article

References (28)

1. D.S. Celermajer, K.E. Sorensen, V.M. Gooch, D.J. Spiegelhalter, O.I. Miller, I.D. Sullivan, et al., Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis, Lancet 340 (1992), 1111-1115
2. L. Chan, A.G. Shaw, F. Busfield, B. Haluska, A. Barnett, J. Kesting, et al., Carotid artery intimal medial thickness, brachial artery flow-mediated vasodilation and cardiovascular risk factors in diabetic and non-diabetic indigenous, Atherosclerosis 180 (2005), 319-326
3. M.N. Cruz, L. Luksha, H. Logman, L. Poston, S. Agewall and K. Kublickiene, Acute responses to phytoestrogens in small arteries from men with coronary heart disease, Am J Physiol Heart Circ Physiol 290 (2006), H1969-H1975
4. S. Das and D.K. Das, Anti-inflammatory responses of resveratrol, Inflamm Allergy Drug Targets 6 (2007), 168-173
5. P.F. Dotto Bau, C.H.D. Bau, A.A. Naujorks and G.A. Rosito, Early and late effects of alcohol ingestion on blood pressure and endothelial function, Alcohol 37 (2005), 53-58
6. S.S. Goh, O.L. Woodman, S. Pepe, A.H. Cao, C. Qin and R.H. Ritchie, The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms, Antiox Redox Signal 9 (2007), 101-113
7. L.M. Hung, J.K. Chen, S.S. Huang, R.S. Lee and M.J. Su, Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes, Cardiovasc Res 47 (2000), 549-555
8. Joseph A. Baur and David A. Sinclair, Therapeutic potential of resveratrol: The in vivo evidence, Nat Rev Drug Discov 5 (2006), 493-506
9. P. Kollar, H. Kotolova, J. Necas, M. Karṕisek, L. Bartosikova and P. Karesova, Experimental study of resveratrol and flavonoids in red wine with regard to their possible hypolipemic effects, Vnitr Lek 46 (2000), 856-860
10. J. Lekakis, L.S. Rallidis, I. Andreadou, G. Vamvakou, G. Kazantzoglu, P. Magiatis, et al., Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease, Eur J Cardiovasc Prev Rehabil 12 (2005), 596-600
11. R. Liew, M.A. Stagg, K.T. Macleod and P. Collins, The red wine polyphenol, resveratrol, exerts acute direct actions on guinea-pig ventricular myocytes, Eur J Pharmacol 519 (2005), 1-8
12. Z.S. Marton, B. Horvath, T. Alexy, G. Kesmarky, Z.S. Gyevnar, L. Czopf, et al., Follow-up of hemorheological parameters and platelet aggregation in patients with acute coronary syndromes, Clin Hemorheol Microcirc 29 (2003), 81-94
13. E.R. Olson, J.E. Naugle, X. Zhang, J.A. Bomser and J.G. Meszaros, Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol, Am J Physiol 288 (2005), H1131-H1138
14. C.R. Pace-Asciak, O. Rounova, S.E. Hahn, E.P. Diamandis and D.M. Goldberg, Wines and grape juices as modulators of platelet aggregation in healthy human subjects, Clin Chim Acta 246 (1996), 163-182
15. A. Palfi, E. Bartha, L. Copf, L. Mark, F. Gallyas Jr., B. Veres, E. Kalman, L. Pajor, K. Toth, R. Ohmacht and B. Sumegi, Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C alpha/beta II, J Nutr Biochem 20 (2008), 418-425
16. O. Rakici, U. Kiziltepe, B. Coskun, S. Aslamaci and F. Akar, Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery, Int J Cardiol 105 (2005), 209-215
17. S. Renaud and M. De Lorgeril, Wine, alcohol, platelets, and the French paradox for coronary heart disease, Lancet 339 (1992), 1523-1526
18. M. Sato, P.S. Ray, G. Maulik, N. Maulik, R.M. Engelman, A.A. Bertelli, et al., Myocardial protection with red wine extract, J Cardiovasc Pharmacol 35 (2000), 263-268
19. V. Scḧachinger, M.B. Britten and A.M. Zeiher, Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease, Circulation 101 (2000), 1899-1906
20. C. Silan, The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats, Biol Pharm Bull 31 (2008), 897-902
21. J.H. Stein, J.G. Keevil, D.A. Wiebe, S. Aeschlimann and J.D. Folts, Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease, Circulation 100 (1999), 1050-1055
22. M.F. Stoddard, A.C. Pearson, M.J. Kern, J. Ratcliff, D.G. Mrosek and A.J. Labovitz, Left ventricular diastolic function: Comparison of pulsed Doppler echocardiographic and hemodynamic indexes in subjects with and without coronary artery disease, J Am Coll Cardiol 13 (1989), 327-336
23. T. Wallerath, G. Deckert, T. Ternes, H. Anderson, H. Li, K. Witte, et al., Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase, Circulation 106 (2002), 1652-1658
24. Z. Wang, Y. Huang, J. Zou, K. Cao, Y. Xu, J.M. Wu, Effects of red wine and wine polyphenol resveratrol on platelet agggregation in vivo and in vitro, Int J Mol Med 9 (2002), 77-79
25. Z. Wang, J. Zou, T.C. Hsieh, Y. Huang and J.M. Wu, Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels, Int J Mol Med 16 (2005), 553-640
26. C.C. Wu, C.I. Wu, W.Y. Wang and Y.C. Wu, Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins, Planta Med 73 (2007), 439-444
27. L. Zhaoping, S.Yan, Z. Xiaopeng, L. Zeqing, Z.Wenzhong, M.Weifeng, et al., Effects of trans-resveratrol on hypertensioninduced cardiac hypertrophy using the partially nephrectomized rat model, Clin Exp Pharmacol Physiol 32 (2005), 1049-1054
28. W. Zhirong, Z. Jiangang, H. Yuanzhu, C. Kejiang, X. Yinan and J.M. Wu, Effect of resveratrol on platelet aggregation in vivo and in vitro, Chinese Med J 115 (2002), 378-380